Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827151 | 0.90 | KDM4E (0.58) | L3MBTL1MEN1KMT2AABCB1KDM4E | |
| SCHEMBL11840409 | 0.83 | ALOX5 (0.59) | L3MBTL1MEN1KMT2AABCB1KDM4E | |
| SCHEMBL13752163 | 0.78 | KDM4E (0.60) | MEN1KMT2AABCB1KDM4EHSD17B10 | |
| SCHEMBL6565776 | 0.78 | L3MBTL1 (0.70) | L3MBTL1ABCB1MAPTALOX5GAA | |
| SCHEMBL17085323 | 0.77 | KDM4E (0.54) | KMT2AABCB1KDM4EHSD17B10MAPT | |
| SCHEMBL28468685 | 0.77 | GAA (0.63) | MEN1KMT2AABCB1KDM4ETSHR | |
| SCHEMBL13401380 | 0.76 | KDM4E (0.59) | L3MBTL1MEN1KMT2AABCB1KDM4E | |
| SCHEMBL5469169 | 0.76 | ABCB1 (0.54) | L3MBTL1MEN1KMT2AABCB1KDM4E | |
| SCHEMBL11838953 | 0.76 | LMNA (0.52) | KMT2AABCB1KDM4EHSD17B10MAPT | |
| SCHEMBL10828858 | 0.75 | KDM4E (0.45) | L3MBTL1MEN1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399426-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | Active Pass Pharmaceuticals, Inc. (CA) | 2004-03-24 | — | — | EP | disclosed |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-10-09 | — | — | US | disclosed |
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2002100836-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2002-12-19 | — | — | WO | disclosed |
| US-3940394-A | ANTILIPEMIC | SANTILLI ARTHUR A | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125338-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | L3MBTL1 4771/4885MEN1 4646/4885KMT2A 4534/4885 |
| US-20030191144-A1 | Compounds, compositions and methods for modulating beta-amyloid production | APP, PPARA, PPARG | L3MBTL1 4771/4885MEN1 4646/4885KMT2A 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.